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Abstract
Background: Infections with polyomavirus BK virus (BKV) are a common cause of renal dysfunction after renal
transplantation and may also be harmful in surgical patients with shock. The aim of the present study was to
determine the frequency of BKV viremia in critically ill surgical patients with septic or hemorrhagic shock, and, if
viremia is detectable, whether viremia may be associated with renal dysfunction.
Findings: A total of 125 plasma samples from 44 critically ill surgical patients with septic or hemorrhagic shock
were tested by real-time polymerase chain reaction (PCR) for BKV DNA during their stay on the intensive care unit
(ICU). BKV viremia occurred in four patients, i.e. in three of the septic and in one of the hemorrhagic shock group.
There was no association between viremia and renal dysfunction. All positive samples contained a low viral load
(< 500 copies/ml).
Conclusions: Since BK viremia was rarely found and with low viral load only in critically ill surgical patients with
shock, it is very unlikely that BK viremia results in BK nephropathy later on.
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Background
Infections with BK virus (BKV) are an increasing pro-
blem and a common cause of renal dysfunction after
allograft renal transplantation [1,2]. IgG seroprevalence
for BK virus (BKV) was 82% in healthy blood donors,
and, over a period of 14 months, no BKV viruria was
detectable [3]. Kaneko and colleagues reported preva-
lence of BKV in urine samples in about 13.5% of the
healthy control group, 33.3% of patients with chronic
renal disease, and 55.6% of patients with renal disease
under cortisone therapy [4].
Critically ill nonimmunosuppressed patients with
either trauma or sepsis have been reported to demon-
strate immunologic features consistent with immuno-
suppression ("immunoparalysis”), i.e. cytomegalovirus or
herpes simplex virus reactivation or infections [5-8].
Thus, we hypothesized that BKV viremia might also
occur in critically ill surgical patients. Since the appear-
ance of a BKV nephropathy was strongly associated with
the viral load detected in renal transplant patient’s
blood [1], we focused on detection of viral load in the
blood of surgical critically ill patients. The aim of the
present study was to determine the frequency of BKV
viremia in surgical critically ill patients with hemorrha-
gic or septic shock.
Methods
Patients and data collection
The prospective study is in compliance with the Hel-
sinki declaration and was approved by the Independent
Ethics Committee of the University Ulm (65/07). All
surgical patients admitted to the Anaesthesiology adult
ICU between August 2008 and December 2008 with
severe SIRS/sepsis, septic or haemorrhagic shock on
admission or developing septic or haemorrhagic shock
on the ICU were included in the present study, in total,
51 cases ≥ 18 years with shock. Four patients of the
hypovolaemic shock group and three patients of the sep-
tic shock group had to be excluded from further analy-
sis, due to refusal of informed consent, stay < 24 hours
on ICU, early demission to another ICU or concomitant
cardiogenic shock. Thus, in total, blood samples of 44
critically ill shock patients were included for analysis of
BKV deoxyribonucleic acid (DNA), 18 in the septic
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shock group and 26 in the hemorrhagic shock group
(http://ClinicalTrials.gov ID: NCT00736827). Blood sam-
ples were taken before, during and after shock: on the
first days of severe SIRS/sepsis; shock with a noradrena-
line dose in μg/kg × min of > 0 and ≤ 0.1 > 2 h, > 0.1 and
≤ 1.0 > 2 h, > 1.0 > 2 h, or > 1.0 + adrenaline > 2 h; after
septic shock; before demission from the ICU or before
death.
Diagnosis of sepsis, acute kidney injury (AKI) and severity
of organ dysfunctions and of disease
Sepsis and septic shock were defined using the 2003
SCCM/ESICM/ACCP/ATS/SIS sepsis definitions [9].
Shock was defined as hypotension despite adequate
volume resuscitation, a systolic blood pressure of ≤ 90
mmHg, or the need of vasopressors to keep blood pres-
sure ≥ 90 mmHg.
Acute kidney injury (AKI) was defined by the Acute
Kidney Injury Network criteria [10], which are based on
acute alterations in serum creatinine or urine output.
Severity of organ dysfunctions was evaluated daily by
the SOFA score (Sequential Organ Failure Assessment)
[11], and of sepsis by the 2003 sepsis definitions [9].
Severity of disease on admission was monitored by the
SAPS 3 score (Simplified Acute Physiology Score 3) [12]
and the APACHE II score (Acute Physiology and
Chronic Health Evaluation II) [13].
Blood samples
Blood samples were taken from arterial lines of the
patients at the ICU. Samples were immediately centri-
fuged and plasma was stored at -20°C until testing.
Detection of BKV DNA by real-time PCR
The presence of BKV DNA was tested via real-time poly-
merase chain reaction (PCR) [14]. DNA was extracted
from 200 μl of the plasma samples using the High Pure
viral nucleic acid kit (Roche, Mannheim, Germany)
according to the instructions of the manufacturer. The
efficiency of the nucleic acid purification was controlled by
co-extraction and subsequent amplification of Herpes
virus saimiri DNA. The BKV real-time PCR was per-
formed in a final volume of 20 μl consisting of 5 μl of
DNA, primers, probe at a final concentration of 200 nM
each, and 1 × Quantitect probe master mix (QIAGEN,
Hilden, Germany). For real-time BK PCR, primer 1 with
sequence (5’-3’)AGCAGGCAAGGGTTCTATTAC-
TAAAT, primer 2 with GAAGCAACAGCAGATTCT-
CAACA, and probe with AAGACCCTAAAGACTTTCC
CTCTGATCTACACCAGTTT were used [14]. Amplifica-
tion was performed on a 7500 real-time PCR system
(Applied Biosystems, Darmstadt, Germany). The cycling
conditions were 50 cycles with 30 s at 95°C and 60 s at
60°C after a preheating step of 15 min at 95°C. The lower
limit of quantification was 300 copies/ml. General labora-
tory procedures to prevent PCR contamination were
strictly adhered to. One negative probe was extracted and
amplified for every five samples.
Statistical analyses
Rates of BKV DNA detection in blood of consecutive
patients are given. No statistical analyses were
performed.
Results
The study included 44 patients, 18 in septic shock and
26 in hemorrhagic shock.
Patient’s characteristics and scores are summarized in
Table 1. Median total stay in the ICU was 9 days (range
2-52) and in the hospital 30 days (range 3-117), respec-
tively. Twenty-two patients had no acute kidney injury
(AKI), and 22 AKI stages 1 to 3. 9/44 patients required
renal replacement therapy (RRT).
At least two, and up to five blood samples were col-
lected per patient. A total of 125 plasma samples was
analyzed for BKV DNA. Results regarding viral load
before, during and after shock are given in Table 2. In
total, five blood samples of four patients were tested posi-
tive for BKV DNA. The viral load in all positive samples
was low (≤4.4 × 102 copies/ml). One septic shock patient,
only, revealed AKI stage 2 at maximum and BKV viremia.
None of the four BKV positive patients needed RRT
(Tables 1 and 2). None of the nine patients with RRT was
tested positive for BKV viral DNA.
Discussion
The main result of the present study is that BKV vire-
mia was rarely found in critically ill surgical patients
with shock and with low viral load, only.
Due to the small sample size, conclusions have to be
drawn with caution. We focused on BKV viremia, since
BKV nephropathy with renal failure has been reported to
be strongly associated with viral load in patient’s blood [1].
All patients with a low viral load (< 1.9 × 105 copies/ml)
had a stable renal function without treatment [1]. Thus,
our results with low viral load (≤4.4 × 102 copies/ml) and
only one BK positive patient revealing AKI stage 2, are in
agreement with these data [1].
In immunosuppressed patients, onset of viruria and
viremia occurred 40.5 days (range: 0-415 days) and 60
days (range: 18-276 days) post renal transplantation
[15]. Median onset of BKV replication in urine by
detecting decoy cells was estimated at 16 weeks (range:
2-69 weeks), of viral DNA in blood at 23 weeks (range:
4-73 weeks), and of BK polyoma virus associated
nephropathy (PyVAN) at 28 weeks (range: 8-86 weeks)
following renal transplantation [16]. Thus, only patient 5
(Table 2) was in the range, BKV nephropathy might
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have been detected, underlying the reported range of 56
up to 602 days [16]. Thus, our observation period may
have been too short to detect BK nephropathy.
In the present study, diagnosis of AKI was based on
current clinical definitions [10], which do not reflect the
underlying pathogenetic mechanisms of BK-PyVAN,
diagnosed by renal biopsy and histologically on tubular-
interstitial nephropathy [17].
In renal transplant recipients, a high BK viral load in
plasma (> 10000 copies/ml) for more than three weeks
suggests that BK-PyVAN is highly likely, i.e. “presumptive
BK-PyVAN” [18]. In our four patients with BK viremia,
viral load was low and did not exceed three weeks, making
BK-PyVAN very unlikely. Decoy cells and viral DNA in
urine are used for screening purposes and response to
therapeutic interventions for BK-PyVAN. Due to low viral
load in blood in our patients, these screening methods
might have detected more cases of BK reactivation, how-
ever, with even minor relevance for the clinician since
large nucleus decoy cells do not necessarily point to the
development of BK-PyVAN.
Studies in non-renal solid organ transplant recipients
have shown variable prevalence of BK viruria and scarcely
BK viremia during the first post-transplant year and in
allograft recipients with deteriorating renal function, and
presence of BKV in urine or blood was not associated with
Table 1 Patient characteristics and scores
Total Shock RRT Maximal acute kidney injury
stage
Hemor-
rhagic
Septic Yes No Stage
0
Stage
1
Stage
2
Stage
3
Patients n = 44 26 18 9 35 22 13 6 3
Age, years Median
Range
56.5 52.5 60 69 53 54.5 51 68.5 63
20-
88
20-81 37-88 45-
73
20-
88
21-88 20-81 60-71 45-70
Male/female n = 35/9 19/7 16/2 8/1 27/8 16/6 11/2 5/1 3/0
Stay in hospital before ICU, days Median 1 1 4 3 1 1 0 5 2
Range 0-36 0-14 0-36 0-15 0-36 0-36 0-19 2-15 2-5
Days on ICU Median 9 8 12 17 7 6 15 17 25
Range 2-52 3-52 2-34 3-43 2-52 2-24 3-28 7-52 5-34
Stay in hospital after ICU Median 12 9 17 5 15 12 11 17 11
Range 0-
111
0-48 0-111 0-41 0-
111
0-111 0-46 0-41 11-25
Days in hospital Median 30 24.5 44 24 31 24 29 54 50
Range 3-
117
3-73 3-117 3-73 5-
117
3-117 3-65 20-73 18-52
Period under BKV observation, days before + on
ICU
Median 14 10 19.5 20 13 7.5 16 26.5 27
Range 3-57 3-57 3-43 3-57 3-54 3-43 3-35 9-57 7-39
SOFA score Median 9 8 9 13 8 7.5 9 9.5 12
Range 3-18 3-15 5-18 9-18 3-12 4-12 3-18 7-15 10-16
SAPS3 score Median 45 47 42.5 66 45 45 45 56.5 45
Range 24-
87
26-87 24-87 26-
87
24-
71
33-71 24-87 39-87 26-68
APACHE II score Median 20 22.5 18 30 20 21 18 24.5 18
Range 10-
45
10-45 11-37 16-
45
10-
36
11-30 10-37 15-45 16-33
ICU survival/death 39/5 24/2 15/3 6/3 33/2 21/1 10/3 5/1 3/0
RRT/no RRT 9/35 3/23 6/12 / / 1/21 3/10 3/3 2/1
Total days with AKI Median 1 0 1 7 0 0 1 8 20
Range 0-26 0-13 0-26 0-26 0-8 0 1-9 2-13 4-26
AKI on demission from hospital n = 13 4 9 5 8 2 7 3 1
BKV reactivation n = 4 1 3 0 4 3 0 1 0
AKI acute kidney injury; RRT renal replacement therapy; SOFA highest value during ICU stay; SAPS3 and APACHE II: value on admission to ICU
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Table 2 BKV reactivation in patients with hemorrhagic or septic shock
Pat.
no.
Shock
group
Days in
hospital
before ICU
Days
on
ICU
Days in
hospital after
ICU
Total days
in hospital
Day at ICU with
BKV detection
Viral load
(copies/ml)
Survival AKI 1
days
AKI 2
days
AKI 3
days
AKI stage
on
demission
1st day
severe SIRS/
sepsis
1st
day
shock
1st day
after shock
before
demission/
death
37 hemorrhagic 0 11 4 15 4 < 300* + 0 0 0 0
5 septic 0 6 111 117 2 440 + 0 0 0 0
19 septic 2 4 0 6 2 and 4 < 300 < 300 - 0 0 0 0
29 septic 6 15 25 46 3 < 300 + 6 2 0 2
*300: BKV DNA weakly positive below the limit of quantification
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worse renal function [1,19-24]. Thus, a second, organ-spe-
cific hit, such as donor-recipient human leukocyte antigen
mismatch, appeared to be necessary for the final develop-
ment of BK viremia and/or nephropathy [24]. A missing
second hit and an adequate humoral immune response
[25] in our four BK positive patients may have contributed
to avoidance of high level BK viremia and presumptive or
manifest BK-PyVAN.
Conclusions
In conclusion, BKV viremia in critically ill surgical hae-
morrhagic and septic shock patients appears to be rare
and associated with low BK viremia, only. Thus, it is
very unlikely that BKV viremia results in nephropathy
later on in these patients.
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